Program
benserazide, levodopa drug combination
Also written as “HRG2010 Capsule, Sinemet®, Madopar®”, “Madopar® 250” and “levodopa/benserazide”.
Its studies are mostly in Parkinson Disease, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bial - Portela C | 20 open or running | phase 1since Jan 24, 2012 | Jan 24, 2012 | none ahead |
| Jiangsu HengRui Medicine | 10 open or running | phase 1since May 9, 2025 | May 9, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 24, 2012First study: phase 1 study in Parkinson DiseaseNew to Bial - Portela CBial - Portela C · NCT01533116 · 52 enrolled · Canada
- Mar 27, 2017Phase 1 study in Parkinson DiseaseBial - Portela C · NCT03097211 · 38 enrolled · Portugal
- May 9, 2025Jiangsu HengRui Medicine’s first study: phase 1 study in Parkinson DiseaseNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT06976346 · 16 enrolled · China
TargetBeta
“An orally available combination of benserazide, an aromatic L-amino acid decarboxylase (AADC) inhibitor, and levodopa, an inert, metabolic precursor to dopamine, with dopaminergic and antiparkinsonian properties”NCIt, by rule
Other programs on DDC
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Carbidoparule | Novartis | phase 4 | 25 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06976346Parkinson Disease · China | 1 | Completed | Jiangsu HengRui Medicine | Oct 7, 2021 | 16 |
| NCT03097211Parkinson Disease · Portugal | 1 | Completed | Bial - Portela C | Oct 20, 2006 | 38 |
| NCT01533116Parkinson Disease · Canada | 1 | Completed | Bial - Portela C | Aug 2009 | 52 |
How it is read
Names in the registry
- “HRG2010 Capsule, Sinemet®, Madopar®”, 1 entry
- “Madopar® 250”, 1 entry
- “levodopa/benserazide”, 1 entry
Conditions, from the studies’ own filings
- Parkinson Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.